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Inhibition of CRISPR-Cas9 ribonucleoprotein
complex assembly by anti-CRISPR AcrIIC2
Annoj Thavalingam1,15, Zhi Cheng2,3,15, Bianca Garcia4,15, Xue Huang2,5,15, Megha Shah1, Wei Sun2,
Min Wang2, Lucas Harrington6, Sungwon Hwang1, Yurima Hidalgo-Reyes4, Erik J. Sontheimer 7,8,
Jennifer Doudna 6,9,10,11,12,13, Alan R. Davidson 1,4, Trevor F. Moraes1, Yanli Wang2,3,14 &
Karen L. Maxwell 1
CRISPR-Cas adaptive immune systems function to protect bacteria from invasion by foreign
genetic elements. The CRISPR-Cas9 system has been widely adopted as a powerful genome-
editing tool, and phage-encoded inhibitors, known as anti-CRISPRs, offer a means of reg-
ulating its activity. Here, we report the crystal structures of anti-CRISPR protein AcrIIC2Nme
alone and in complex with Nme1Cas9. We demonstrate that AcrIIC2Nme inhibits Cas9
through interactions with the positively charged bridge helix, thereby preventing sgRNA
loading. In vivo phage plaque assays and in vitro DNA cleavage assays show that AcrIIC2Nme
mediates its activity through a large electronegative surface. This work shows that anti-
CRISPR activity can be mediated through the inhibition of Cas9 complex assembly.
https://doi.org/10.1038/s41467-019-10577-3 OPEN
1 Department of Biochemistry, University of Toronto, 661 University Avenue, Suite 1600, Toronto, ON M5G 1M1, Canada. 2 Key Laboratory of RNA Biology,
CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China. 3 University of Chinese
Academy of Sciences, Beijing 100049, China. 4Department of Molecular Genetics, University of Toronto, 661 University Avenue, Suite 1600, Toronto, ON
M5G 1M1, Canada. 5 Hefei National Research Center for Physical Sciences at the Microscale, School of Life Sciences, University of Science and Technology of
China, Hefei 230027 Anhui, China. 6Department of Molecular and Cell Biology, University of California, Berkeley, Berkeley, CA 94720, USA. 7 RNA
Therapeutics Institute, University of Massachusetts Medical School, Worcester, MA 01605, USA. 8 Program in Molecular Medicine, University of
Massachusetts Medical School, Worcester, MA 01605, USA. 9Molecular Biophysics and Integrated Bioimaging Division, Lawrence Berkeley National
Laboratory, Berkeley, CA 94720, USA. 10 Innovative Genomics Institute, University of California, Berkeley, CA 94704, USA. 11 Howard Hughes Medical
Institute, University of California, Berkeley, CA 94720, USA. 12Department of Chemistry, University of California, Berkeley, CA 94720, USA. 13 Gladstone
Institutes, San Francisco, CA 94158, USA. 14National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101,
China. 15These authors contributed equally: Annoj Thavalingam, Zhi Cheng, Bianca Garcia, Xue Huang. Correspondence and requests for materials should be
addressed to Y.W. (email: ylwang@ibp.ac.cn) or to K.L.M. (email: karen.maxwell@utoronto.ca)
NATURE COMMUNICATIONS |         (2019) 10:2806 | https://doi.org/10.1038/s41467-019-10577-3 | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
CRISPR-Cas systems provide adaptive immunity that pro-tects bacteria and archaea against invasion by phages,plasmids, and other foreign genetic elements1–3. When a
bacterial cell is invaded by a phage, the CRISPR-Cas system
acquires a short segment of the phage genome and integrates it
into the CRISPR locus where it can serve as a template for the
production of mature CRISPR RNA (crRNA) molecules. These
crRNAs form a complex with either a single protein effector or a
multi-subunit effector complex that targets and degrades invad-
ing nucleic acids in a sequence-speciﬁc manner. CRISPR-Cas
systems are divided into two classes, which can be further sub-
divided into six types and 33 subtypes, including their variants4.
Class 1 systems (types I, III, and IV) form multi-subunit effector
complexes, while Class 2 systems (types II, V, and VI) use a single
protein to target invading genetic elements5. The type II protein,
Cas9, has been widely adapted as a molecular tool for genome
editing purposes.
In response to the evolutionary pressures posed by active
CRISPR-Cas systems, phages have evolved protein inhibitors of
these systems. The ﬁrst described anti-CRISPR proteins were
active against the type I-E and I-F systems in Pseudomonas aer-
uginosa6–8. Subsequently, anti-CRISPR proteins were identiﬁed
against type II-C9,10, type II-A11–13, type I-D14, type I-C15, and
type V-A15,16 CRISPR-Cas systems. The protein sequences of
these anti-CRISPRs display high sequence diversity and the
mechanisms by which they function also vary widely. Within the
type I systems, anti-CRISPRs AcrIF1, AcrIF2, and AcrIF10 have
been shown to interact directly with the Cascade complex and
block DNA binding17–21. AcrIF3 interacts with the Cas3 nuclease
and prevents its recruitment to the DNA-bound Cascade com-
plex22, while AcrIF10 acts as a DNA mimic, binding to the basic
residues that are critical for DNA binding. The mechanisms of
activity of the type II anti-CRISPRs have proven to be similarly
varied. Type II-C anti-CRISPR AcrIIC1 was shown to bind
directly to the Cas9 HNH domain and prevent cleavage of the
target DNA strand, while AcrIIC3 was shown to induce Cas9
dimerization and thereby inhibit DNA binding activity23.
AcrIIA4 and AcrIIA2, which inhibit type II-A Cas9 proteins, were
shown to occupy the PAM-interacting site, interacting with the
RuvC, CTD, and TOPO domains of SpyCas9, and inhibiting the
nuclease activity of SpyCas9 through multiple mechanisms24.
Thus, previously characterized anti-CRISPRs function either
through inhibition of nuclease activity or by blocking target DNA
binding.
As Cas9 is a large multi-functional protein that mediates its
activities through multiple domains, it provides a variety of sur-
faces that could potentially be targeted by anti-CRISPRs. Cas9 is
composed of two lobes, the α-helical recognition (REC) lobe and
the nuclease (NUC) lobe. The NUC lobe contains the HNH and
RuvC endonuclease domains that are required for DNA cleavage
activity, and the more variable PAM-interacting domain (PID).
The two lobes are connected by the arginine-rich bridge helix.
The PID is largely disordered in the apo-Cas9 structure, which
prevents target DNA recognition in the absence of guide RNA.
The transition of Cas9 to its active conformation requires binding
of a guide RNA molecule25,26. This results in substantial struc-
tural rearrangements, with the most prominent conformational
changes taking place in the REC lobe27. Binding to both target
DNA and guide RNA are thought to be key regulators of Cas9
enzyme function26.
In this work, we investigate the mechanism of activity of anti-
CRISPR protein AcrIIC2Nme. This 123-residue protein was pre-
viously shown to inhibit the activity of Neisseria meningitidis
CRISPR-Cas9 in vivo and in vitro9,23. We show that AcrIIC2Nme
functions by inhibiting loading of the guide RNA molecule,
thereby preventing formation of the active CRISPR-Cas9
surveillance complex. As previously characterized mechanisms of
anti-CRISPR activity all target fully assembled CRISPR-Cas
complexes, AcrIIC2Nme provides a unique mechanism for anti-
CRISPR activity.
Results
AcrIIC2Nme binds to the bridge helix. We previously showed
that anti-CRISPR protein AcrIIC2Nme was able to robustly inhibit
the cleavage activity of the N. meningitidis type II-C CRISPR-
Cas9 protein9,23. As other anti-CRISPRs have been shown to have
activity against multiple Cas9 orthologues23, we investigated the
range of activity of AcrIIC2Nme using an in vivo phage-targeting
assay (Fig. 1a). In this assay, the Cas9 protein is expressed from a
plasmid in Escherichia coli together with an sgRNA that targets E.
coli phage Mu. This CRISPR targeting prevents phage Mu from
forming plaques. In the presence of a functional anti-CRISPR
protein, phage Mu is able to successfully infect the bacterial cell,
leading to plaque formation. We determined that AcrIIC2Nme was
able to fully inhibit the activity of its cognate type II-C Cas9
protein from N. meningitidis (Nme1Cas9), as well as a homolog
from Haemophilus parainﬂuenzae (HpaCas9) that shares 65%
sequence identity10. By contrast, AcrIIC2Nme showed very poor
inhibitory activity against the type II-C Cas9 proteins from
Geobacillus stearothermophilus (GeoCas9) and Campylobacter
jejuni (CjeCas9), which share only 38% and 31% sequence
identity with Nme1Cas9. These results are consistent with our
previous work that showed AcrIIC2Nme inhibits Nme1Cas9
and HpaCas9, but not more distantly related Cas9 proteins
in vitro10,23.
To gain insight into how AcrIIC2Nme inhibits Cas9 activity, we
set out to identify the domain with which it interacts. Full-length
Nme1Cas9 was susceptible to degradation in vivo and many of its
isolated domains were insoluble. Thus, we used the closely related
HpaCas9 for these studies because the holoenzyme and isolated
domains were considerably more stable than Nme1Cas9. We co-
expressed untagged AcrIIC2Nme with 6-His-tagged HpaCas9 in E.
coli and puriﬁed the resulting complex using Ni-afﬁnity
chromatography. AcrIIC2Nme co-puriﬁed with Cas9, showing a
speciﬁc interaction between the two proteins (Fig. 1b). We next
tested for interactions with isolated Cas9 domains, including the
HNH domain, the guide RNA recognition (REC) lobe, and the
PID (Fig. 1c). We found that AcrIIC2Nme co-eluted from the Ni-
NTA column with the REC lobe (Fig. 1b). To further delineate
the region of the REC lobe with which AcrIIC2Nme interacts, we
created a construct lacking the N-terminal arginine-rich bridge
helix (REC-ΔBH). AcrIIC2Nme was unable to stably interact with
this domain. To determine if the bridge helix alone was sufﬁcient
for AcrIIC2Nme binding to Cas9, we created a deletion mutant of
Cas9 that maintained the bridge helix but lacked the REC1 and
REC2 domains (ΔREC1/2). AcrIIC2Nme still bound to this
protein. Consistent with the bridge helix interaction, AcrIIC2Nme
did not bind to the isolated HNH or PID and was able to bind to
Cas9 in their absence (Fig. 1b). These results indicate that the
bridge helix is the primary binding site for AcrIIC2Nme.
The interaction of AcrIIC2Nme inhibits sgRNA binding. The
Cas9 REC lobe mediates sgRNA binding28. To determine the
effects of AcrIIC2Nme on sgRNA binding, we co-expressed it in E.
coli with His-tagged Nme1Cas9 and sgRNA and puriﬁed the
resulting complex using afﬁnity chromatography. AcrIIC2Nme co-
puriﬁed with Nme1Cas9, but no sgRNA was bound to the
complex (Fig. 2a). By contrast, when Nme1Cas9-sgRNA was co-
expressed with a type I-E anti-CRISPR protein, which does not
inhibit Cas9, the sgRNA co-puriﬁed with Nme1Cas9 (Fig. 2a).
Thus, the interaction of AcrIIC2Nme with Nme1Cas9 appears to
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block sgRNA binding to Nme1Cas9. In addition, we observed
increased proteolysis of Nme1Cas9 when it was co-expressed with
AcrIIC2Nme (Fig. 2a). Previous work has shown that the Cas9 apo
protein binding to guide RNA results in conformational changes
that render the protein more resistant to proteolysis26,29,30. These
conformational changes are required to form the active complex
for target DNA cleavage. The increased sensitivity of Cas9 to
cellular proteases in the presence of AcrIIC2Nme is consistent with
its role in blocking sgRNA binding. To further probe whether the
binding of AcrIIC2Nme affects the assembly of the Nme1Cas9-
sgRNA surveillance complex, we performed limited α-
chymotrypsin proteolysis. Both apo-Nme1Cas9 and
AcrIIC2Nme-bound Nme1Cas9 were sensitive to α-chymotrypsin,
and they exhibited similar digestion patterns (Supplementary
Fig. 1A). By contrast, Nme1Cas9 bound to sgRNA or sgRNA/
target DNA showed increased resistance to proteolysis (Supple-
mentary Fig. 1B). When apo-Nme1Cas9 was pre-incubated with
AcrIIC2Nme and then sgRNA or sgRNA/target DNA was added,
the digestion patterns were similar to those observed for apo-
Nme1Cas9, indicating that prior interaction with AcrIIC2Nme
blocked sgRNA binding (Supplementary Fig. 1C). Finally, size
exclusion chromatography was used to verify that AcrIIC2Nme
forms a stable complex with Nme1Cas9 but is unable to interact
with sgRNA-bound Nme1Cas9 complex (Fig. 2b). Taken toge-
ther, these results imply that AcrIIC2Nme inhibits Nme1Cas9 by
disrupting the assembly of the Nme1Cas9-sgRNA complex.
To validate our observation that AcrIIC2Nme inhibits the
loading of sgRNA onto Nme1Cas9, we tested the ability of
Nme1Cas9 to bind sgRNA in the absence and presence of
AcrIIC2Nme using a ﬁlter-binding assay. This revealed that
addition of AcrIIC2Nme at a four-fold molar ratio decreased the
afﬁnity of binding of sgRNA to Nme1Cas9 (Fig. 2c). Using
isothermal calorimetry (ITC) we calculated binding afﬁnities for
AcrIIC2Nme and sgRNA to apo-Nme1Cas9. We determined that
AcrIIC2Nme bound with a Kd of 200 nM, while the afﬁnity of the
sgRNA was ten times greater (Kd= 23 nM; Supplementary Fig. 2).
When we added a two-fold molar excess of AcrIIC2Nme to
Nme1Cas9 before sgRNA addition, we found that the afﬁnity of
sgRNA binding decreased to 76 nM. When a 20-fold molar excess
of AcrIIC2Nme was added before sgRNA, the afﬁnity of sgRNA
binding decreased further, to 3.2 μM. Gel ﬁltration chromato-
graphy was also used to analyze the equilibrium complexes
formed under these reaction conditions. We found that some
Nme1Cas9-sgRNA complex was present in the presence of a two-
fold excess of AcrIIC2Nme, but not in the presence of 10-fold
excess AcrIIC2Nme (Supplementary Fig. 3A). These results
indicate that AcrIIC2Nme competes with sgRNA for the binding
site on Nme1Cas9 and prevents formation of the active
surveillance complex.
We next used in vitro competition assays to evaluate the
competition between AcrIIC2Nme and sgRNA for the binding
site on Nme1Cas9. When sgRNA was mixed with Nme1Cas9,
and then AcrIIC2Nme was added to this pre-formed complex,
there was no inhibition of DNA cleavage (Fig. 2d). When
AcrIIC2Nme was pre-bound to Nme1Cas9 at a ratio of 2:1 and
then an equal amount of sgRNA was added, we found complete
inhibition of DNA cleavage in vitro (Fig. 2d, Supplementary
Fig. 3B). However, when sgRNA and AcrIIC2Nme were added
simultaneously, a two-fold excess of AcrIIC2Nme did not
appreciably inhibit Nme1Cas9 activity (Supplementary Fig. 3B).
In fact greater than 10-fold excess of anti-CRISPR was required
to block DNA cleavage activity under these conditions
(Supplementary Fig. 3B). Collectively, these data show that
the anti-CRISPR and sgRNA directly compete for the same
binding site. AcrIIC2Nme is able to interact with Nme1Cas9 and
block its activity through disruption of sgRNA binding,
however, it does not efﬁciently inhibit the activity of the pre-
formed surveillance complex due to its weaker binding
interaction with Nme1Cas9.
AcrIIC2Nme has an electronegative functional surface. To better
understand the precise mechanism by which AcrIIC2Nme inhibits
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Fig. 1 AcrIIC2Nme inhibits Cas9 activity through an interaction with the bridge helix. a Plaquing of E. coli phage Mu targeted by type II-C Cas9 proteins
(Nme1Cas9, HpaCas9, GeoCas9, CjeCas9) in the presence of AcrIIC2Nme, a type II-C anti-CRISPR with broad activity (AcrIIC1Nme) and a type I anti-CRISPR
(AcrIE2). The sequence identity of the Cas9 proteins as compared to Nme1Cas9 is noted to the right of the ﬁgure. b Untagged anti-CRISPR was co-puriﬁed
with 6x-His-tagged full-length HpaCas9, or domains thereof (c) using Ni-NTA afﬁnity chromatography and the bound proteins were analyzed by SDS-
PAGE and visualized using Coomassie staining. c Schematics of HpaCas9 truncations used to identify the domain with which AcrIIC2Nme interacts. The
bridge helix is denoted in dark gray, and the three sequence regions that comprise the RuvC domain are denoted as I, II, and III
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Cas9 activity, we determined its crystal structure to a resolution
of 2.5 Å using single-wavelength anomalous diffraction (SAD).
All X-ray data collection and reﬁnement statistics are sum-
marized in Table 1. To date, the structures of 11 anti-CRISPR
proteins have been determined [for review see ref. 31]. These
anti-CRISPR families share no sequence identity and all display
very different protein structures. Consistent with these previous
observations, AcrIIC2Nme shares no sequence or structural
similarity with previously characterized anti-CRISPR proteins.
A DALI search32 of the Protein Data Bank also did not reveal
any signiﬁcant similarity to any previously determined struc-
ture. The protein architecture of AcrIIC2Nme consists of a six-
stranded β-sheet composed of two anti-parallel β-strands
followed by a Greek key motif, all wrapped around a 20-residue
α-helix (Fig. 3a).
We also solved the crystal structure of AcrIIC2Nme in complex
with Nme1Cas9 to a resolution of 2.6 Å. We found that
AcrIIC2Nme bound to Nme1Cas9 in the same dimeric form as
observed in the unbound state (Fig. 3b, c). Unexpectedly, only
residues 16–77 of Nme1Cas9, corresponding to the bridge helix
region and a partial fragment I of the RuvC domain, were
observed in the complex (Supplementary Fig. 4A). Analysis of the
AcrIIC2-Nme1Cas9 crystal by SDS-PAGE revealed that the rest
of Nme1Cas9 was digested during crystallization. To conﬁrm this
ﬁnding, we treated the AcrIIC2-Nme1Cas9 complex with α-
chymotrypsin protease, and then crystalized the digested
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complex. We solved this structure to a resolution of 2.3 Å and
found that it was similar to the structure discussed above
(Supplementary Fig. 4B and C). This further conﬁrms that the
bridge helix is the primary target for AcrIIC2Nme activity.
We next analyzed interactions between AcrIIC2Nme and
Nme1Cas9. As shown in Fig. 3d, the AcrIIC2Nme monomers
form a dimer with a negatively charged surface on one side into
which the arginine-rich bridge helix nestles. Four residues from
each of the AcrIIC2Nme monomers, E17, E24, D108, and N112,
make interactions with the bridge helix (Fig. 3e, f). In AcrIIC2.1,
the side-chain of E17 hydrogen bonds with Nme1Cas9 residues
R69 and R73, E24 interacts with residues R73 and R74, while
D108 and N112 form hydrogen bonds with the side-chain of R74.
Similarly, the side-chains of E24, D108, E17, and N112 of
AcrIIC2.2 interact with Nme1Cas9 residues R62, R66, R69,
and R70.
To determine if the interactions between AcrIIC2Nme and the
bridge helix of Nme1Cas9 are required and sufﬁcient for anti-
CRISPR inhibitory activity, we mutated 19 residues distributed
widely across the surface of AcrIIC2Nme (Fig. 4a and Table 2). We
also created a mutant lacking the ﬁnal 12 amino acids
(Δ112–123), which were not resolved in one of the apo crystal
structures. The anti-CRISPR activity of each mutant was tested
using the in vivo phage-targeting assay, in which expression of
wild type AcrIIC2Nme inactivates Nme1Cas9 and allows phage
Mu to plaque. Mutation of three of the four amino acids that
make direct contacts with the bridge helix (E17A, E24A, D108A)
displayed a complete lack of anti-CRISPR activity in vivo (Fig. 4b
and Table 2) while the other mutants showed changes in activity
of less than 10-fold. Deletion of residue N112 (Δ112–123 mutant)
did not affect activity. In vitro DNA cleavage assays further
veriﬁed these results. Substitution of E17, E24, and D108 with Ala
severely inhibited the activity of AcrIIC2Nme, as did the variant
E24D (Fig. 2d). By contrast, mutants that maintained the negative
charge at two of these positions (E17D and D108E) had similar
levels of inhibition to that of wild type AcrIIC2Nme. Circular
Table 1 Data collection and reﬁnement statistics
AcrIIC2 AcrIIC2 Se-AcrIIC2 AcrIIC2-Nme1Cas9 AcrIIC2-Nme1Cas9-proteolysis
Data collection
PDB code 6N05 6JD7 – 6JDJ 6JDX
Space group P43212 C2 P6322 P212121 P212121
Cell dimensions
a, b, c (Å) 71.9, 71.9, 135.1 105.6, 73.5, 81.1 73.6, 73.6, 105.8 61.4, 77.4, 106.9 56.3, 77.4, 107.5
α, β, γ (°) 90.0, 90.0, 90.0 90.0, 129.8, 90.0 90.0, 120.0, 90.0 90.0, 90.0, 90.0 90.0, 90.0, 90.0
Wavelength (Å) 0.9789 0.97900 0.97918 0.97891 0.97894
Resolution (Å) 49.23–2.5
(2.59–2.50)
50.00–2.45
(2.49–2.45)
40.72–2.54
(2.58–2.54)
50.00–2.60
(2.64–2.60)
50–2.28
(2.32–2.28)
Rmerge 0.0979 (2.157) 0.074 (0.288) 0.138 (2.423) 0.154 (0.900) 0.087 (1.071)
Total reﬂections 181,759 90,912 214,497 198,730 235,170
Unique reﬂections 12,871 17,826 6026 16,424 21,775
I/σI 23.8 (1.45) 19.7 (4.6) 21.4 (2.1) 18.5 (2.3) 26.6 (2.3)
Completeness (%) 99.9 (100) 99.7 (99.7) 99.9 (100) 99.9 (99.4) 99.1 (99.9)
Redundancy 14.1 (14.7) 5.1 (5.1) 35.6 (39.7) 12.1 (9.4) 10.8 (10.7)
Reﬁnement
Resolution (Å) 49.23–2.5 40.00–2.45 38.68–2.60 45.01–2.28
No. reﬂections 12,868 17,318 15,017 17,199
Rwork/Rfree 0.212/0.247 0.194/0.197 0.194/0.227 0.208/0.222
No. atoms
Protein 1743 2781 2263 2226
Ligand/ion 0 5 0 4
Water 11 256 74 61
B-factors
Protein 89.21 42.06 42.93 36.83
Ligand/ion 48.31 20.00
Water 65.45 40.11 40.18 32.61
R.m.s. deviations
Bond lengths (Å) 0.008 0.020 0.005 0.019
Bond angles (°) 1.03 1.479 0.996 1.343
Values in parentheses are for highest-resolution shell
Table 2 In vivo phage plaquing assays
Residue substitution Fold reduction in titre
K9A <10
E17A 107
R19A <10
E21A <10
N22A <10
E24A 107
E24K <10
D42A <10
T45A <10
E47A <10
K51A <10
P52A <10
E62A <10
R64A <10
N84A <10
N85A <10
K86A <10
K88A <10
E91A <10
D108A 107
D108E <10
Δ112–123 <10
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dichroism spectroscopy of the three mutants with abrogated
in vivo activity revealed spectra similar to the wild type protein
(Fig. 4c), showing that the lack of activity was not due to a folding
defect. In addition, cooperative thermal denaturation curves and
melting temperatures similar to the wild type protein (Table 3)
indicated that these mutants maintained stable, folded structures.
We conclude that the negatively charged surface of AcrIIC2Nme
and the positively charged Nme1Cas9 bridge helix comprise a
critical interaction interface that is required for anti-CRISPR
activity.
To further validate this functional surface, we assayed the
ability of non-functional AcrIIC2Nme mutants to inhibit sgRNA
binding. We co-expressed His-tagged Nme1Cas9 with its sgRNA
from a plasmid in E. coli and introduced a second plasmid that
expressed either wild type AcrIIC2Nme, one of the inactive
mutants, or a type I-E anti-CRISPR protein. Using nickel afﬁnity
chromatography we puriﬁed Nme1Cas9 and the associated
sgRNA and anti-CRISPR proteins. In the absence of anti-
CRISPR or in the presence of a control anti-CRISPR that targets
the type I-E system, sgRNA co-puriﬁed with Nme1Cas9 (Fig. 4d).
In the presence of wild type AcrIIC2Nme, no sgRNA co-puriﬁed,
conﬁrming the ability of this anti-CRISPR to block sgRNA
binding in vivo. The inactive mutants showed varying levels of
binding to Nme1Cas9, resulting in varying levels of inhibition of
sgRNA binding (Fig. 4d). E17A was severely compromised, while
E24A showed some inhibition of sgRNA binding, but not as
strong as the wild type anti-CRISPR protein. Interestingly, both
E24A and D108A maintained the ability to bind to Nme1Cas9,
but were outcompeted by the sgRNA when it was added to the
pre-formed AcrIIC2Nme-Nme1Cas9 complex (Supplementary
Fig. 5A,B). Moreover, a double mutant, E17A/E24A, was
completely outcompeted by the sgRNA (Supplementary Fig. 5C).
These results further conﬁrm that the acidic residues of
AcrIIC2Nme are crucial for the inhibition of Nme1Cas9.
We next examined residues in the Nme1Cas9 bridge helix that
interact with AcrIIC2Nme in the crystal structure. We ﬁrst targeted
position R62 and showed that substitution with Ala decreased
inhibition of Nme1Cas9 by wild type AcrIIC2Nme. By contrast,
substitution with Lys, which maintains the charge interaction with
residue E24 in AcrIIC2Nme, allowed the anti-CRISPR to retain its
inhibitory activity (Fig. 4e). These data suggest that the interaction
between R62 of Nme1Cas9 and E24 of AcrIIC2.2 is crucial for
inhibition. Similarly, mutation of position R69 in the bridge helix
of Nme1Cas9, which slightly decreased DNA cleavage activity,
dramatically reduced the inhibitory activity of AcrIIC2Nme.
Substitution of four other positively charged residues in the
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and β-strand structural elements. Monomers are colored in violet and deep salmon, and the N- and C-termini are noted. b Cartoon representation of
AcrIIC2-Nme1Cas9 complex. c Surface representation of AcrIIC2-Nme1Cas9 complex. d Electrostatic surface potential of AcrIIC2-Nme1Cas9 complex.
e, f Interactions between the bridge helix and AcrIIC2Nme. The bridge helix is shown in cyan. AcrIIC2.1 and AcrIIC2.2 are shown in violet and deep salmon,
respectively
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-10577-3
6 NATURE COMMUNICATIONS |         (2019) 10:2806 | https://doi.org/10.1038/s41467-019-10577-3 | www.nature.com/naturecommunications
bridge helix (R66A, R70A, R73A, and R74A) had little effect on
the inhibitory activity of AcrIIC2Nme (Fig. 4e). Together, these
results indicate that the interactions between AcrIIC2Nme and the
bridge helix of Nme1Cas9 are essential for inhibition.
To determine if the sequence of the bridge helix is sufﬁcient for
inhibition by AcrIIC2Nme, we compared the amino acid sequence
of Nme1Cas9, which is robustly inhibited by AcrIIC2Nme, with
SpyCas9, which is not inhibited. We identiﬁed two positions in
the SpyCas9 bridge helix (T62 and T73) that are arginine residues
in Nme1Cas9 (Fig. 4f). We substituted these positions singly and
in combination, and discovered that the in vitro DNA cleavage
activity of the SpyCas9 double mutant was inhibited by
AcrIIC2Nme (Fig. 4g). This further conﬁrms the importance of
the interaction between AcrIIC2Nme and the bridge helix of Cas9.
It also emphasizes a potential role for anti-CRISPRs in driving
Cas9 evolution.
AcrIIC2Nme blocks binding of sgRNA stem loops 1 and 2. To
further establish the impact of AcrIIC2Nme binding on the
assembly of Nme1Cas9 with sgRNA, we compared the structure
a
Phage Mu
WT
E17A
E24A
D108A
b
No Acr
Ca
s9+
sgR
NA
Ca
s9 
alo
ne
WT E1
7A
E2
4A
E2
4K
AcrIIC2
Ac
rIE
2
NmeCas9
AcrIIC2
sgRNA
d
e
f
Uncleaved
Cleaved
Cleaved
R6
2K
R7
4K
R6
2A
W
T
No
ne
– – – – –
R6
6A
R6
9A
R7
0A
R7
3A
R7
4A
– – – – – ++++ + + + + + – + – +M AcrIIC2
–1200
–1000
–800
–600
–400
–200
0
200
200 220 240 260
M
ol
ar
 e
llip
tic
ity
 ×
 1
0–
3
(de
g ×
 cm
2 /d
m
ol
) 
Wavelength (nm)
c
g 
M
Bases
150
(bp)
100
250
500
750
1000
2000
3000
5000
(bp)
Nme1Cas9
55 60 65 70 75 80 85 90
SpyCas9
M – + – + – + – +No
ne WT T62R T73R
AcrIIC2
T62R/
T73R
100
250
500
750
1000
2000
3000
5000
20
25
35
48
100
63
kDa
75
11
Uncleaved
Cleaved
Cleaved
R6
2A
/R
69
A
R6
9A
/R
70
A
Fig. 4 AcrIIC2Nme activity is mediated through a large electronegative surface. a AcrIIC2Nme surface-exposed residues targeted for site-directed
mutagenesis are shown on the surface of the protein. The side chain positions at which amino acid substitutions did not affect activity are shown in gray,
while the three residues that showed the large decrease in activity when substituted are shown in red. b Representative results of the in vivo phage
plaque assay. Serial dilutions of phage Mu plated on E. coli reveal that E17A, E24A, and D108A mutants have lost the ability to inhibit CRISPR-Cas9.
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show that the inactive mutants maintain their secondary structure. d Co-puriﬁcation of AcrIIC2Nme mutants with 6x-His-tagged Nme1Cas9 reveals
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Table 3 Thermal stability values (Tm) derived by circular
dichroism spectroscopy
AcrIIC2 construct Tm (°C)
WT 55.7 ± 0.6
E17A 59.7 ± 0.8
E24A 59.0 ± 0.9
D108A 61.8 ± 0.5
Source data are provided as a Source Data ﬁle
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of AcrIIC2Nme bound to Nme1Cas9 with the Nme1Cas9-sgRNA
binary complex by aligning the bridge helix regions. The struc-
tural superposition shows that two AcrIIC2Nme monomers make
major clashes with stem loops 1 and 2, and slightly overlap the
seed region of the sgRNA (Fig. 5a). Monomer AcrIIC2.2 occupies
the major groove of stem loop 2, displacing the duplex formed by
nucleotides 125–131:98–90 and the adjacent single-stranded
region at the 5′-end of the sgRNA (Fig. 5b). Monomer
AcrIIC2.1 occupies the positions of nucleotides 84–87 and seed
region from nucleotides 20–23 (Fig. 5c). To conﬁrm the impor-
tance of these interactions, we assessed the ability of truncated
sgRNA constructs to bind Nme1Cas9 in the presence of
AcrIIC2Nme. We found that the 5′ cr:tracr duplex bound to Cas9
with equal afﬁnities in the presence and absence of AcrIIC2Nme
(Fig. 5d, e). By contrast, the interaction of the 3′ stem loops was
inhibited in the presence of AcrIIC2Nme (Fig. 5d, f). These
terminal stem loops have been shown to assist in stabilizing the
sgRNA and supporting stable complex formation with the Cas9
protein33. These results conﬁrm that AcrIIC2Nme interferes with
sgRNA binding through an interaction that blocks the binding
site of the stem loops 1 and 2.
Discussion
In this work, we investigated the mechanism of activity of anti-
CRISPR protein AcrIIC2Nme. We found that it blocks Cas9
binding to sgRNA, thereby inhibiting biogenesis of the surveil-
lance complex. This interference is mediated through an inter-
action with the arginine-rich bridge helix, which connects the
REC lobe to the NUC lobe. High-resolution studies of Cas9-
sgRNA complexes with and without target DNA bound show that
the bridge helix contacts the sgRNA, in particular the region that
pairs with nucleotides nearest the PAM sequence in the target
DNA28,34. The crystal structure of AcrIIC2Nme revealed a highly
negatively charged surface that binds to the positively charged
bridge helix. Mutation of this electronegative surface decreases
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the afﬁnity of AcrIIC2Nme for Cas9, resulting in loss of anti-
CRISPR activity. The bridge helix, which forms part of the
endonuclease functional core, is a universal feature of Cas9 pro-
teins26 and thus provides a reliable target for inhibition by anti-
CRISPR proteins. The targeting of a highly conserved domain by
AcrIIC2Nme is similar to that observed for AcrIIC1Nme, which was
shown to target the HNH endonuclease domain for inhibition23.
Other previously characterized type I and type II anti-CRISPRs
revealed two general mechanisms for blocking CRISPR-Cas
activity. The most common mechanism observed to date is
inhibition of DNA binding through a direct interaction with the
CRISPR surveillance complex. The second mechanism is blocking
DNA cleavage by inhibiting nuclease activity, either through
interaction with a Cas9 endonuclease domain23 or the Cas3
endonuclease protein in type I systems17,22. The mechanism of
activity for AcrIIC2Nme that we determined in this study, dis-
ruption of CRISPR-Cas surveillance complex assembly through
an interaction with the bridge helix, is in agreement with the
study recently published by Zhu et al. in which they examined
mechanisms of inhibition for anti-CRISPR proteins AcrIIC2Nme
and AcrIIC3Nme35. Like Zhu et al., we found that pre-binding
sgRNA to Nme1Cas9 greatly reduced the ability of AcrIIC2Nme to
interact with the complex and inhibit DNA cleavage activity due
to its much lower afﬁnity for Cas9 as compared to the sgRNA.
Using structural and biochemical analyses, we showed that
AcrIIC2Nme competes for the binding site of the sgRNA stem
loops 1 and 2. In the natural CRISPR-Cas9 system, where the
crRNA and tracrRNA are separate molecules instead of a single
fused molecule as in the case of the sgRNA, AcrIIC2Nme may
compete more effectively with the tracrRNA for binding to Cas9.
This might endow the anti-CRISPR with an increased ability to
disrupt pre-formed surveillance complexes that are present in the
cell when the phage infects.
In addition to blocking the surveillance complex formation, the
activity of AcrIIC2Nme leaves the Cas9 protein trapped in its apo
form, which is much more sensitive to the activity of cellular pro-
teases than are the RNA- and DNA-bound forms. Thus, the
introduction of this anti-CRISPR into a cell may lead to a decrease
in the steady state levels of full-length Cas9 in the cell, providing an
additional mechanism of anti-CRISPR activity. This activity of
AcrIIC2Nme may explain the differences we observed in the in vivo
and in vitro assays. When AcrIIC2Nme was co-expressed with
Nme1Cas9 in vivo and the resulting complex was puriﬁed, no
sgRNA was found to be associated with the complex (Fig. 2a). This
contrasted with in vitro experiments, in which a great excess of anti-
CRISPR was required to inhibit sgRNA binding. AcrIIC2Nme is
robustly produced, soluble to high concentration, and resistant to
bacterial proteases in E. coli. It accumulates to high levels in the cell
that allow it to bind to Nme1Cas9 immediately as the Cas9 protein
is being produced. The sgRNA, by contrast, is probably less stable in
the cell due to the activity of cellular nucleases. For these reasons,
the anti-CRISPR likely has a larger competitive advantage in vivo as
compared with the puriﬁed in vitro system. The reduction of
Nme1Cas9 steady-state levels in the presence of AcrIIC2Nme was
previously observed in mammalian cells10, and probably also con-
tributes to the ability of AcrIIC2Nme to efﬁciently inhibit genome
editing in these cells. Other anti-CRISPRs that inhibit DNA binding
or interfere with nuclease activity do not appear to share this type of
two-pronged inhibitory mechanism. Additionally, the activity of
AcrIIC2Nme may also serve to inhibit spacer acquisition, which has
been shown to be Cas9-dependent36,37.
Inhibiting the formation of the active CRISPR-Cas9 surveillance
complex intuitively seems that it would not provide an advantage to
infecting phages, as they could not overcome the pre-assembled
surveillance complexes. However, recent work has shown that
multiple phages need to infect a cell in order to provide a critical
mass of anti-CRISPR protein to overwhelm the CRISPR
system38,39. Even anti-CRISPRs that inhibit fully formed surveil-
lance complexes fail to inactivate the CRISPR-Cas system if the
phage population numbers fall below a critical threshold. When
phages infect but fail to replicate in cells with active CRISPR sys-
tems, they still produce small amounts of anti-CRISPR proteins that
leave the bacterial cell in an immunocompromised state. Thus,
AcrIIC2Nme molecules produced by a phage that was ultimately
destroyed by Cas9 could persist within the cell and inhibit CRISPR-
Cas complexes assembled after the infection. This would, in turn,
increase the likelihood of successful replication by the next infecting
phage. The expression of AcrIIC2Nme would also be an effective
means for a prophage to keep the CRISPR system turned off once it
integrated into the host genome. Thus, a phage encoding an anti-
CRISPR that prevents assembly of the CRISPR-Cas9 complex may
not be at an evolutionarily disadvantage to one that inhibits the pre-
formed complex. The distinct mechanism of activity of AcrIIC2Nme,
inhibiting assembly of a CRISPR-Cas complex, further emphasizes
the amazing diversity of inhibitors that phages have evolved to
counteract the existential challenge posed by CRISPR-Cas systems.
Methods
Plasmid construction. Plasmids encoding the Cas9 proteins used in the in vivo
phage-targeting assay were generated by Gibson assembly using primers listed in
Supplementary Table 1. The pGeoCas9-sgRNA plasmid23 was used as the starting
vector. GeoCas9 and its sgRNA were replaced with the variant Cas9 proteins and
their corresponding sgRNAs (sequences listed in Supplementary Table 1). The
sgRNAs were synthetized as part of gblock fragments (IDT) along with overhangs
to clone using Gibson assembly. All fragments used in the assembly reactions were
ﬁrst ampliﬁed using Phusion High-Fidelity DNA Polymerase (Thermo Fisher
Scientiﬁc). The reactions were prepared according to manufacturer’s recommen-
dations and 2 μL of the assembly reaction solution were transformed in High
Efﬁciency chemically competent E. coli cells (New England Biolabs). Clones were
screened by restriction digestion and were sequence-veriﬁed. The Cas9-encoding
plasmids were linearized with BsaI and ligated to DNA encoding crRNA targeting
phage Mu, which were generated by annealing of two complementary oligonu-
cleotides carrying overhanging BsaI ends.
For expression and protein puriﬁcation in E. coli, NcoI-HindIII DNA inserts
encoding wild type and mutant AcrIIC2Nme proteins from pCDF-1b plasmids were
sub-cloned into a pHAT440 expression plasmid such that the protein was expressed
with an N-terminal 6-His tag. The boundaries for the HpaCas9 HNH, PID, and
REC domains were determined by alignment with GeoCas9, whose domain
boundaries were previously described23. These domains were cloned into
expression plasmid pCDF-1b with a 6-His tag fused to their C-termini. Point
mutations in acrIIC2Nme were generated by site-directed mutagenesis. The desired
nucleotide mutations were introduced in the middle of 40 bp complementary
primers (Supplementary Table 1). Sixteen PCR cycles were performed using
Phusion® High-ﬁdelity DNA polymerase (ThermoScientiﬁc), and the PCR
products were treated with DpnI endonuclease. The sample was ethanol
precipitated and transformed into DH5α cells. Plasmids were isolated and
mutations conﬁrmed by sequencing.
Phage plaque assays. Plasmids expressing the different Cas9 proteins containing
a spacer targeting phage Mu were co-transformed in BB101 cells with a plasmid
expressing wild type or mutant AcrIIC2Nme. Cells containing both plasmids were
subcultured in Lysogeny broth (LB) supplemented with chloramphenicol and
streptomycin and grown for 2 h, at which point anti-CRISPR expression was
induced with 0.01 mM IPTG for 3 h. 200 μL of cells were mixed with soft agar and
top-plated on LB supplemented with both antibiotics and 200 ng mL−1 aTc, 0.2%
arabinose, and 10 mM MgSO4. Serial dilutions of phage Mu were spotted on top
and the plates were incubated overnight at 37 °C. Experiments were performed in
triplicate, with representative replicates shown in the ﬁgure panels.
Cas9-AcrIIC2Nme pull-down experiments. E. coli BL21 cells were co-transformed
with 6-His-tagged HpaCas9 constructs in a pMCSG7 backbone10, and a pCDF-1b
vector encoding untagged AcrIIC2Nme. Cells were grown in Terriﬁc Broth (TB) at
37 °C to an optical density of 0.8. Protein expression was induced by the addition of
1 mM IPTG for 18 h at 16 °C. Cells were lysed by sonication in binding buffer
(50 mM Tris pH 7.5, 200 mM NaCl, 5% Glycerol, 20 mM Imidazole). Clariﬁed
lysates were bound to Ni-NTA agarose (Qiagen) for 30 min at 4 °C, washed with
binding buffer supplemented with 30 mM imidazole and bound protein was eluted
with buffer containing 300 mM imidazole. 6-His-tagged Nme1Cas9+ sgRNA9
ribonucleoprotein with wild type or mutant AcrIIC2Nme was puriﬁed using the
same protocol. Complexes were analyzed by SDS-PAGE on a 15% Tris–Tricine gel
and visualized by Coomassie staining. The amount of bound sgRNA was examined
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using a 12.5% polyacrylamide/urea gel and visualized by SYBR Gold (Thermo
Fisher Scientiﬁc) staining. Experiments were performed in triplicate, with repre-
sentative replicates shown in the ﬁgure panels.
Filter binding assays. Filter binding was performed as described previously23. Filter
binding was conducted in 1× Binding Buffer (20mM Tris, pH 7.5, 100mM KCl, 5
mM MgCl2, 1 mM DTT, 5% (vol/vol) glycerol, 0.01% Igepal CA-630, 10 μgmL−1
yeast tRNA, and 10 μgmL−1 BSA). Nme1Cas9 was mixed with a 4× molar ratio of
AcrIIC2Nme at the maximum concentration in Binding Buffer and was diluted in 1×
Binding Buffer. Less than 0.01 nM radiolabeled sgRNA or the indicated guide trun-
cation was added and allowed to incubate for 30min at 37 °C. During incubation
Tufryn (Pall Corporation), Protran (Whatman), and Hybond-N+ (GE Healthcare)
membranes were soaked in Binding Buffer omitting the detergent, yeast tRNA and
BSA and arranged on a dot blot apparatus above two layers of Whatman paper. The
complexing reactions were loaded onto the dot blot apparatus and vacuum was
applied. The membranes were dried and visualized by phosphorimaging and quan-
tiﬁed using ImageQuant. All experiments were carried out in triplicate, with averaged
values shown in the ﬁgure panels. Data were ﬁt to a binding isotherm using Prism
(GraphPad Software), and Kd values of 0.24 ± 0.14 nM for sgRNA alone, and 2.2 ± 1.3
nM in the presence of AcrIIC2Nme were determined.
The sgRNA sequences for the truncation binding experiments are as follows:
Full length sgRNA—GGTCTGTAAGCGGATGCCATATGGTTGTAGCTCC
CTTTCTCGAAAGAGAACCGTTGCTACAATAAGGCCGTCTGAAAAGATGT
GCCGCAACGCTCTGCCCCTTAAAGCTTCTGCTTTAACGGGCTT
Repeat:anti-repeat—GGTTGTAGCTCCCTTTCTCGAAAGAGAACCGTTGC
TACAATAA
SL1 and SL2—GGCCGTCTGAAAAGATGTGCCGCAACGCTCTGCCCCT
TAAAGCTTCTGCTTTAACGGGCTT
Isothermal titration calorimetry. Nme1Cas9, AcrIIC2Nme, sgRNA and (Nme1-
Cas9-AcrIIC2Nme) complexes of 1:2, 1:10, and 1:20 molar ratios were extensively
dialyzed against a buffer containing 300 mM NaCl, 20 mM Tris, pH 7.5. Titrations
were performed using a MicroCal PEAQ-ITC system (Malvern Instruments) at
20 °C. To determine the afﬁnity of binding for Nme1Cas9 and AcrIIC2Nme, 100 μM
AcrIIC2Nme was titrated into 10 μM Nme1Cas9. To determine the afﬁnities of
sgRNA in the presence and absence of AcrIIC2Nme, 90 μM Nme1Cas9 with or
without AcrIIC2Nme was titrated with 10 μM sgRNA. The resulting ITC curves
were processed using Origin 7.0 software (OriginLab) using the “One Set of Sites”
ﬁtting model. Experiments were carried out in triplicate, with representative
replicates shown in the ﬁgure panels.
Competitive binding assays. AcrIIC2Nme, sgRNA, and Nme1Cas9 (molar ratios of
2:1:1, 3:1:1, or 10:1:1) were mixed together on ice and then centrifuged at 13,800×g
at 4 °C for 10 min. The samples were loaded into a Superdex 200 Increase 10/300
(GE Healthcare) column for separation using gel ﬁltration chromatography. The
buffer used for gel ﬁltration contained 300 mM NaCl, 20 mM Tris, pH 7.5.
In vitro DNA cleavage assays. The pUC19 target DNA plasmid (35 bp target
DNA cloned into the pUC19 vector) was linearized by ScaI digestion before the
cleavage reactions. In the presence or absence of AcrIIC2, the Cas9-sgRNA com-
plex was incubated with 300 ng pUC19 target DNA in 10 μL reaction buffer
containing 20 mM Tris–HCl pH 7.5, 100 mM KCl, 10 mM MgCl2, 1 mM DTT and
5% glycerol. All reactions were stopped by adding 1 μL 0.5 M EDTA and 1 μL
0.1 mgmL−1 Proteinase K for 30 min at room temperature. The reaction products
were run on 1% agarose gels, and gels were stained with ethidium bromide for
product detection. All experiments were carried out at least in triplicate, with
representative replicates shown in the ﬁgure panels.
Competitive cleavage assays. For the competition cleavage assays, two incuba-
tion methods were employed to prepare the samples for DNA cleavage. First,
Nme1Cas9 was incubated with AcrIIC2Nme at molar ratios of 1:0, 1:2, 1:4, 1:10,
1:20, and 1:40 on ice for 15 min, 1.1 fold of sgRNA was added and the samples were
incubated for an additional 15 min. Second, 1.1 fold of sgRNA was simultaneously
mixed with AcrIIC2Nme and Nme1Cas9 and incubated for 15 min on ice. The
resulting enzyme complexes were incubated with 300 ng pUC19 target DNA in
10 μL reaction buffer (20 mM Tris–HCl pH 7.5, 100 mM KCl, 10 mM MgCl2,
1 mM DTT and 5% glycerol). The reactions were allowed to proceed at 37 °C for
10 min, and were stopped by the addition of 1 μL 0.5 M EDTA and 1 μL 0.1 mg
mL−1 Proteinase K. The samples were incubated for 30 min at room temperature
and the reaction products were run on 1% agarose gels and stained with ethidium
bromide for product detection. All experiments were carried out at least in tri-
plicate, with representative replicates shown in the ﬁgure panels.
Puriﬁcation of AcrIIC2Nme. The wild type and mutant AcrIIC2Nme proteins were
expressed in E. coli BL21 and puriﬁed as described previously9. Selenomethionine
(Se-Met) labeled AcrIIC2Nme was expressed using the methionine auxotrophic E.
coli BL21(DE3) B834 strain cultured in M9 minimal media containing trace metals
and supplemented with selenomethionine.
Far-UV circular dichroism scans and thermal denaturation. Puriﬁed wild type
and mutant AcrIIC2Nme proteins were dialyzed into 10 mM Tris pH 7.5, 0.2 mM
EDTA, 250 mM KCl. The proteins were scanned on a Jasco J-810 CD Spectro-
polarimeter from 200 to 260 nm. Each scan was an average of ﬁve accumulations
performed at 20 nmmin−1. For the thermal denaturation experiment, the proteins
were heated at a rate of 1 °C min−1 from 20 to 90 °C, and the state of protein
folding was assessed by absorbance at 218 nm. The assay was carried out with three
biological replicates, and the standard deviation presented as the margin of error.
Protein puriﬁcation for Nme1Cas9-AcrIIC2Nme co-crystals. Full-length genes of
AcrIIC2Nme and Nme1Cas9 were purchased from Sangon Biotech, and cloned into
an expression vector pET28a-Sumo with His6-Sumo tag at the N-terminus.
Mutants were constructed using a site-directed mutagenesis kit. All proteins were
overexpressed in E. coli Rosetta (DE3) (Novagen) cells and were induced with
0.1 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG) at OD600= 0.6 for 12 h at
18 °C. Cells containing Nme1Cas9 were lysed by sonication in buffer containing in
20 mM Tris–HCl and 0.5 M NaCl, pH 7.5, at 4 °C. After centrifugation, the
supernatant was puriﬁed by Ni Sepharose resin (GE Healthcare). Eluted Nme1Cas9
protein with His6-sumo-tag was digested with ubiquitin-like protein 1 (Ulp1)
protease and dialyzed against 20 mM Tris–HCl, 0.3 M NaCl for 2 h at 4 °C to
remove the His6-Sumo tag. Nme1Cas9 protein was further puriﬁed by Ni
Sepharose column. Fractions were collected and puriﬁed on an SP column (GE
Healthcare), eluting with buffer containing 20 mM Tris–HCl, pH 7.5, 1 M NaCl.
Crystallization and structure determination of AcrIIC2Nme. Native and (Se-Met)
Ni-NTA afﬁnity-puriﬁed AcrIIC2Nme proteins were further puriﬁed by size
exclusion chromatography using a Superdex 75 column in buffer containing 20
mM Tris–HCl pH 7.5, 100 mM NaCl, 5 mM β-mercaptoethanol. Puriﬁed
AcrIIC2Nme was initially screened with 1:1 (protein:precipitant) ratio against the
MCSG commercial suite and JCSG+ commercial screen using sitting drop vapor
diffusion at 10 mgmL−1. AcrIIC2Nme crystals were observed in 0.1 M sodium
citrate, 5% propanol, and 20% PEG 4000. The crystals were further optimized with
a 1:1 ratio sitting drop at 20 °C in a precipitant condition composed of 0.1 M
sodium citrate, 5% propanol and 18% PEG 4000 and 15% glycerol, yielding single
crystals in space group P41212. Crystallographic data was collected on crystals
frozen at 105 K on the 08B1-1 beam line at Canadian Light Source (CLS). Dif-
fraction data from a total of 360 images were collected at wavelengths of 0.9795
using 1° oscillations. Data were processed with XDS package to a resolution of 2.5
Å. A complete model for AcrIIC2Nme was solved by Se-SAD with anomalous signal
from Se atoms using Phenix AutoSol. The ﬁnal model was generated after several
rounds of model building and reﬁnement using Coot and PHENIX reﬁne programs
using TLS, yielding a ﬁnal Rwork/Rfree of 0.19/0.24.
Structure determination of Nme1Cas9-AcrIIC2Nme complex. The Nme1Cas9-
AcrIIC2Nme complex was reconstituted on ice by incubating puriﬁed Nme1Cas9
and AcrIIC2Nme at a molar ratio of 1:10. The resulting complex was puriﬁed by gel
ﬁltration chromatography, concentrated before crystallization to an absorbance of
280 nm to ~15, as measured by Nanodrop 2000, and then set for crystal screen. The
Nme1Cas9-AcrIIC2-proteolysis complex was prepared by mixing Nme1Cas9 with
AcrIIC2Nme protein at a molar ratio of 1:10 on ice for 30 min. Subsequently, the
sample was puriﬁed by gel ﬁltration chromatography. Next, α-chymotrypsin was
incubated with the complex at a mass ratio of 1:500 or 1:1000 before the sample
was used for crystallization.
The Nme1Cas9-AcrIIC2 complex was crystalized at 16 °C by hanging-drop
vapor diffusion method. The Nme1Cas9-AcrIIC2 complex crystals were obtained
by mixing 1 μL of complex solution and 1 μL of reservoir solution (0.1 M HEPES
pH 7.5, 20% PEG 20,000, 0.01 M Phenol). Diffraction datasets were collected at
beamline BL19U1 at Shanghai Synchrotron Radiation Facility and processed with
XDS or HKL2000. The structure of the AcrIIC2-Nme1Cas9 complex was solved by
molecular replacement with the AcrIIC2 dimer as the model. One Nme1Cas9-
AcrIIC2 complex was identiﬁed in the asymmetric unit. The atomic model was
built and reﬁned using the programs Refmac and Phenix.
Limited proteolysis of Nme1Cas9-AcrIIC2Nme complex. Limited α-chymotrypsin
proteolysis assays were performed at 25 °C for different times (0, 10, 30, 60 min)
using proteolysis buffer 20 mM Tris pH 7.5, 300 mM NaCl. The same amount (80
μg) of puriﬁed Nme1Cas9 was used to construct complex Nme1Cas9-sgRNA
(1:1.1), Nme1Cas9-sgRNA-DNA (1:1.1:1.3), Nme1Cas9-AcrIIC2 (1:4), Nme1Cas9-
AcrIIC2-sgRNA (1:4:1.1), Nme1Cas9-AcrIIC2-sgRNA-DNA (1:4:1.1:1.3). The
reactions were stopped by adding 2× SDS loading buffer and quenched for 10 min
at 70 °C. Samples were analyzed on a 15% SDS polyacrylamide gel with
Tris–Glycine buffer.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
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Data availability
Structures have been deposited as PDB ID 6N05, 6JD7, 6JDJ, and 6JDX. All other
datasets generated during and/or analyzed during the current study are available from
the corresponding authors on reasonable request.
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